Professional Documents
Culture Documents
Fulhold 2016-11-Investor-Update
Fulhold 2016-11-Investor-Update
Fulhold Pharma PLC ‐ Investor Update November 2016
1. Research & Development Update:
a) Wound Treatment:
The research led by Professor David Perlin and funded by the U.S. Department of Defense (DoD) has
been successfully completed and the results presented to the DoD. As we expected, the DoD want to
know what the U.S. Food and Drug Administration (FDA) position is regarding both CHD‐FA as an
Active Pharmaceutical Ingredient (API) and the wound gel itself and what Regulatory registrations
we need to have before they direct any more funding to this initiative. In order to satisfy the FDA
and DoD we have been working extensively with Jenson R+, our Regulatory advisors and have
made significant progress in the completion of our Active Drug Master File (ADMF) for
submission to the FDA and the European Medicines Agency (EMA)
finalised the formulation for our first formulated product which is intended to be a gel for
the treatment of drug‐resistant wound infections
engaged Professor Jacques Snyman, our scientific advisor, to draft a Phase 3 protocol for a
human drug‐resistant wound trial
b) Oral Health:
Our Oral Health initiatives continue to be hindered by ‘sensory’ concerns over mouthfeel and smell.
We are currently in discussion with an international formulation company to establish if these can
be overcome.
c) Mode of Action:
Our main focus in the past 6 months has been on characterisation studies at various institutions of
CHD‐FA in preparation for an FDA meeting. Since the AGM good progress has been made in
elucidating the chemical pathways that create the mixture of acids that make up CHD‐FA. This is
critical to our being able to achieve Regulatory approvals and is also proving invaluable to our
understanding of the potential modes of action displayed by CHD‐FA.
d) Xylella:
Testing against Xylella, a bug which is blighting the olive industry, is taking considerably longer than
anticipated due to difficulties in importing the bug and growing the required cultures. This is not
consuming any additional investment but we are looking at alternative testing facilities and
approaches for this.
e) Inflammation:
As we know, CHD‐FA exhibits very good anti‐inflammatory properties. In June, we completed an in
vitro study to complement our in vivo study and human studies. This was undertaken at Washington
Biotech Laboratories in the USA with excellent results. Our anti‐ inflammatory data base is now
complete up to a phase 2 human study for the treatment of eczema.
f) HIV Study
Most will recall that the HIV study in India was halted due to the Indian government banning the
importation of experimental medicines. At the point of stopping the trial the results did not carry
sufficient statistical weight to support the original aims of the trial. However, the trial results have
Author: David Squire, November 2016
Page 1
Fulhold Pharma PLC ‐ Investor Update November 2016
been written up as a safety trial undertaken with immunocompromised patients. No adverse events
were recorded during the 30 months’ duration of the trial and the results will soon be published in a
peer‐reviewed American journal.
g) Veterinary Medicine
In South Africa, we have recently partnered with Dr Gerhard Jordaan to form Fulvidoc to focus on
the veterinary applications of CHD‐FA. So far we have 4 registrations approved with several more in
the pipeline. An important future focus will be a product to treat mastitis in dairy cows. Worldwide
there are grave concerns regarding the use of antibiotics in animal farming and in fact New Zealand
are in the process of passing legislation to outlaw the use of antibiotics in dairy farming. This will
open up huge opportunities for the use of CHD‐FA as a replacement product. This development will
be taking place under the guidance of Dr Annamarie Petzer from Onderstepoort, the world’s leading
authority in udder health.
h) Freeze Drying
For the first time Fulhold has succeeded in drying CHD‐FA to an 'almost' 100% pure powder using a
technique called freeze‐drying. This opens up opportunities for the use of CHD‐FA in areas such as
personal care products. To this end powder is due to be shipped in the next few weeks to Unilever
research laboratories in Mumbai, India for product formulation and testing.
i) Sport Science
Several opportunities have arisen in the sports nutrition market and potential products have been
formulated and presented to interested companies.
2. Regulatory Activities:
As mentioned above, a huge amount of effort has been put into building the ADMF, primarily for the
wound gel / FDA purposes. It is important to note, however, that in normal drug development each
new drug needs its own ADMF. As CHD‐FA is a Platform Technology, we will have a single ADMF that
will cover multiple drug application, which is a huge cost saving to Fulhold. We are working
extensively with Jenson R+ who have been instrumental in ensuring that we build a robust set of
data for both immediate and longer‐term use. It is worthy of note that Jenson helped us secure
Small to Medium size Enterprise status (SME) which will qualify us for an 80% reduction in Scientific
Advice fees from the EMA.
3. Administration:
a) Sales:
South African sales have suffered a sharp decline due mainly to the non‐performance of Ascendis. As
we had an exclusivity arrangement in place with Ascendis in South Africa, this precluded us from
Author: David Squire, November 2016
Page 2
Fulhold Pharma PLC ‐ Investor Update November 2016
doing any other retail pharmacy sales. Due to their non‐performance, however, we have negotiated
the rights down from ‘exclusive’ to ‘non‐exclusive’ and we are now able to enter various other retail
chains. We are currently working with Dischem on their in‐house brand on 10 products.
b) Tax / year(s)‐end accounting: February 2016 financial statements have been finalised and
submitted to Companies house. A copy is available on the Fulhold website or one can be sent on
request.
c) Titan: Now that the financials have been completed we have re‐opened discussions regarding
potentially moving the work from Titan to another service provider. At the moment costs are
prohibitive as we have a good deal with Titan and the Titan staff working on our accounts have
changed and we are receiving a vastly improved service. We will look at all the options and then
decide and communicate the chosen path.
d) Group Structure: We are still weighing up various options as to how to handle the PLC going
forward. Now that we have a better understanding of how it all works and what the true costs are,
the decision may be to keep PLC going, although this will cost £20 000 per annum. It may be
worthwhile to spend the additional £ 10 000 per annum over what any other company structure
would cost as savings on opening a new PLC down the line will be substantially more.
e) Mauritius: In view of all the new international legislation re transfer pricing It was agreed to shut
down Medivic. With the new declaration of beneficial ownership of all bank accounts it was also
deemed necessary to shut down Medicon. This has happened and all the assets have been repacked
into a container and returned to South Africa. We are identifying where to move the API plant to.
We are currently investigating 2 attractive option – one being Ireland and then when we are
successful with the FDA, the USA.
Regards,
David, Hans & Stephen
Author: David Squire, November 2016
Page 3